Entrada Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Net Income	54.95	-6.69	-94.62	-51.16	-26.52	-5.1
Depreciation & Amortization	3.52	2.84	1.9	1.12	0.33	0.1
Loss (Gain) From Sale of Assets	-	-	-	0.07	0.02	-
Loss (Gain) From Sale of Investments	-9.51	-5.78	0.15	-	-	-
Stock-Based Compensation	17.06	13.11	9.9	2.53	0.33	0.29
Other Operating Activities	-	-	-	-	-	-6.27
Change in Accounts Receivable	2.42	-5.88	-	-	-	-
Change in Accounts Payable	0.55	-2.81	5.29	-0.72	0.63	0.37
Change in Unearned Revenue	-105.06	139.98	-	-	-	-
Change in Income Taxes	2.25	4.02	-	-	-	-
Change in Other Net Operating Assets	19.86	1	-16.4	-2.71	-0.35	-0.19
Operating Cash Flow	-13.97	139.8	-93.79	-50.86	-25.57	-10.8
Capital Expenditures	-3.5	-5.61	-2.89	-4.58	-2.32	-0.63
Investment in Securities	-58.62	-132.78	-145.76	-	-	-
Investing Cash Flow	-62.12	-138.4	-148.65	-4.58	-2.32	-0.63
Issuance of Common Stock	102.25	21.04	0.48	191.63	0.25	0.04
Financing Cash Flow	102.25	21.04	0.48	307.46	50.09	0.04
Net Cash Flow	26.17	22.45	-241.96	252.02	22.2	-11.39
Free Cash Flow	-17.46	134.19	-96.67	-55.44	-27.89	-11.43
Free Cash Flow Margin	-8.11%	104.01%	-	-	-	-
Free Cash Flow Per Share	-0.49	4.06	-3.09	-8.85	-25.23	-12.25
Cash Income Tax Paid	14.72	14.72	-	-	-	-
Levered Free Cash Flow	-29.26	149.04	-58.56	-36.26	-17.21	-
Unlevered Free Cash Flow	-29.26	149.04	-58.56	-36.26	-17.21	-
Change in Net Working Capital	82.45	-140.68	6.68	3.37	-1.13	-

Source: S&P Capital IQ. Standard template. Financial Sources.